OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
LMAT$97.3158

LeMaitre Vascular Inc

Advanced Medical Equipment & TechnologyVerified

LeMaitre Vascular Inc maintains a strong liquidity position with a current ratio of 12.89, indicating a robust ability to meet short-term obligations. The company's liquidity_fpt score is high, supported by a cash and equivalents balance of $28.24 million. However, the company's net cash position is negative after subtracting total debt, which may pose a liquidity risk in the medium term. The company's profitability is above the industry median, with a return on equity (ROE) of 14.67% and a return on assets (ROA) of 9.38%. These metrics suggest that LeMaitre Vascular Inc is effectively utilizing its equity and assets to generate returns. The gross profit margin of 71.5% is also strong, indicating efficient cost management and pricing power. Geographically, LeMaitre Vascular Inc's revenue is concentrated in the United States, with a significant portion of its sales derived from domestic operations. The company's exposure to international markets is limited, which may reduce diversification benefits but also insulate it from foreign exchange and geopolitical risks. Looking ahead, the company is projected to experience moderate revenue growth. The current fiscal year is expected to see a 4.5% increase in revenue, with a further 3.2% growth anticipated in the next fiscal year. This growth trajectory is supported by a stable operating cash flow of $81.25 million and a free cash flow of $43.26 million, which provide flexibility for reinvestment and shareholder returns. The company faces several risk factors, including the potential for dilution, although the risk is currently assessed as low. The risk assessment indicates a medium liquidity risk, primarily due to the negative net cash position after accounting for total debt. Additionally, the company's reliance on a single product line and the competitive nature of the medical device industry pose ongoing challenges. Recent events, including the filing of the 10-K for the fiscal year ended December 31, 2023, highlight the company's financial health and strategic direction. The 10-K filing provides detailed insights into the company's operations, financial condition, and risk factors, which are essential for investors to understand the company's performance and future prospects.

30-day price · LMAT-11.85 (-10.9%)
Low$95.46High$118.01Close$97.31As of17 May, 00:00 UTC
Profile
CompanyLeMaitre Vascular Inc
TickerLMAT.O
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. LeMaitre Vascular Inc designs, develops, and markets vascular surgical products used in the treatment of peripheral vascular disease.

Classification. LeMaitre Vascular Inc is classified in the Healthcare sector under the Advanced Medical Equipment & Technology industry with a confidence level of 0.92.

LeMaitre Vascular Inc maintains a strong liquidity position with a current ratio of 12.89, indicating a robust ability to meet short-term obligations. The company's liquidity_fpt score is high, supported by a cash and equivalents balance of $28.24 million. However, the company's net cash position is negative after subtracting total debt, which may pose a liquidity risk in the medium term. The company's profitability is above the industry median, with a return on equity (ROE) of 14.67% and a return on assets (ROA) of 9.38%. These metrics suggest that LeMaitre Vascular Inc is effectively utilizing its equity and assets to generate returns. The gross profit margin of 71.5% is also strong, indicating efficient cost management and pricing power. Geographically, LeMaitre Vascular Inc's revenue is concentrated in the United States, with a significant portion of its sales derived from domestic operations. The company's exposure to international markets is limited, which may reduce diversification benefits but also insulate it from foreign exchange and geopolitical risks. Looking ahead, the company is projected to experience moderate revenue growth. The current fiscal year is expected to see a 4.5% increase in revenue, with a further 3.2% growth anticipated in the next fiscal year. This growth trajectory is supported by a stable operating cash flow of $81.25 million and a free cash flow of $43.26 million, which provide flexibility for reinvestment and shareholder returns. The company faces several risk factors, including the potential for dilution, although the risk is currently assessed as low. The risk assessment indicates a medium liquidity risk, primarily due to the negative net cash position after accounting for total debt. Additionally, the company's reliance on a single product line and the competitive nature of the medical device industry pose ongoing challenges. Recent events, including the filing of the 10-K for the fiscal year ended December 31, 2023, highlight the company's financial health and strategic direction. The 10-K filing provides detailed insights into the company's operations, financial condition, and risk factors, which are essential for investors to understand the company's performance and future prospects.
Key takeaways
  • LeMaitre Vascular Inc has a strong liquidity position with a current ratio of 12.89.
  • The company's profitability is above the industry median, with a ROE of 14.67% and a ROA of 9.38%.
  • Revenue is primarily concentrated in the United States, reducing diversification benefits.
  • The company is projected to experience moderate revenue growth in the next two fiscal years.
  • The risk of dilution is currently assessed as low, but the company faces medium liquidity risk.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$249.6M
Gross profit$178.5M
Operating income$67.9M
Net income$57.7M
R&D
SG&A
D&A
SBC
Operating cash flow$81.3M
CapEx-$6.8M
Free cash flow$43.3M
Total assets$615.7M
Total liabilities$222.2M
Total equity$393.5M
Cash & equivalents$28.2M
Long-term debt$168.6M
Valuation
Market price$97.31
Market cap$2.22B
Enterprise value$2.36B
P/E38.5
Reported non-GAAP P/E
EV/Revenue9.5
EV/Op income34.8
EV/OCF29.1
P/B5.7
P/Tangible book5.7
Tangible book$393.5M
Net cash-$140.4M
Current ratio12.9
Debt/Equity0.4
ROA9.4%
ROE14.7%
Cash conversion1.4%
CapEx/Revenue-2.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Advanced Medical Equipment & Technology · cohort 109 companies
MetricLMATActivity
Op margin27.2%-19.9% medp25 -150.5% · p75 8.7%top quartile
Net margin23.1%-18.4% medp25 -146.8% · p75 8.0%top quartile
Gross margin71.5%49.9% medp25 36.2% · p75 66.3%top quartile
R&D / revenue6.2% medp25 4.7% · p75 12.0%
CapEx / revenue-2.7%-3.5% medp25 -7.8% · p75 -1.4%above median
Debt / equity43.0%14.5% medp25 0.9% · p75 54.2%above median
Observations
IR observations
Mean price target110.86 USD
Median price target113.00 USD
High price target124.00 USD
Low price target94.00 USD
Mean recommendation2.10 (1=strong buy, 5=strong sell)
Strong-buy count3.00
Buy count3.00
Hold count4.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate2.90 USD
Last actual EPS2.52 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 02:09 UTC#6271795f
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 10:46 UTCJob: 57cbc384